Ivabradine Xiromed

Ivabradine, the active ingredient in Ivabradine Xiromed, is a If channel inhibitor presented as an oral tablet for oral use. It reduces heart rate and is used to manage chronic stable angina and heart failure in adult patients.

GNH USA supplies Ivabradine Xiromed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards, provides regulatory‑compliant documentation for global distribution, and ensures products are manufactured under GMP conditions with rigorous quality testing before release.

Ivabradine is indicated for conditions where reduction of heart rate improves clinical outcomes, primarily within the cardiovascular disease spectrum.

- Chronic stable angina: improves exercise tolerance and reduces the frequency of angina attacks. - Heart failure with reduced ejection fraction (NYHA class II‑III): lowers heart rate, decreasing myocardial oxygen demand and supporting symptom control. - Angina pectoris in patients who cannot tolerate beta‑blockers: provides heart‑rate reduction without affecting contractility.

Adverse reactions may range from mild to serious and should be monitored during therapy.

Common Side Effects: - Visual disturbances (phosphenes): transient luminous phenomena. - Bradycardia: resting heart rate below 50 bpm. - Headache. - Dizziness. - Fatigue. - Blurred vision.

Serious or Rare Side Effects: - Symptomatic bradycardia requiring medical intervention. - Atrial fibrillation or other serious arrhythmias. - Severe visual disturbances, including persistent luminous phenomena. - Hypotension. - Hepatic injury. - Allergic reactions such as rash or angioedema.

Before initiating therapy, clinicians should assess patient suitability and monitor for specific risks.

- Heart rate monitoring: ensure resting heart rate >50 bpm before starting. - Hepatic function: avoid or adjust in severe hepatic impairment. - Sick sinus syndrome: contraindicated in patients with this condition. - Concomitant bradycardic agents: use with caution when combined with beta‑blockers or digoxin. - Renal impairment: dose adjustment may be required in moderate to severe renal dysfunction. - Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Ivabradine may interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma concentrations. - Other bradycardic agents (beta‑blockers, digoxin, non‑dihydropyridine calcium channel blockers): risk of excessive heart‑rate reduction. - Verapamil or diltiazem: potentiate bradycardia. - Other If channel inhibitors: additive effect on heart rate.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - Antihypertensive agents: monitor blood pressure and heart rate. - Diuretics: watch for electrolyte disturbances that could affect cardiac conduction.